Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial
ConclusionIntracoronary infusion of allogeneic CDCs in patients with post-MI LV dysfunction was safe but did not reduce scar size relative to placebo at 6 months. Nevertheless, the reductions in LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs.Trial registrationClinicaltrials.gov identifier: NCT01458405.
Source: European Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiomyopathy | Dilated Cardiomyopathy | Heart | Heart Attack | Heart Failure | Heart Transplant | MRI Scan | Muscular Dystrophy | Myocarditis | Reflex Sympathetic Dystrophy | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Ventricular Tachycardia